|

PIPAC with Nal-IRI Clinical Trials

1 actively recruiting trial

Also known as: Onivyde

Pipeline

Phase 1: 1

Top Sponsors

  • University Hospital, Ghent1

Indications

  • Bile Duct Cancer1
  • Peritoneal Carcinomatosis1
  • Peritoneal Metastases1
  • Appendix Cancer1
  • Pancreatic Cancer1

Other1 trial

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.